Biostar Pharmaceuticals, Inc. (BSPM) Stock Price & Analysis

Biostar Pharmaceuticals, Inc. (BSPM) closed at USD 0 on Thursday, October 22, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 0; the Oct 22, 2026 session ranged USD 0–0 on volume of 150 shares. Market capitalization is $263, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, retrieved October 24, 2026 at 02:20 UTC.

Also available as compact Markdown for AI agents: nexqual.com/BSPM.md

Key facts (BSPM)

Analysts (BSPM)

Consensus None.

Total return (dividends reinvested) (BSPM)

1Y (from 2025-10-24)5Y (from 2021-10-25)
Total return+0.0%-99.7%
S&P 500 (SPY)+13.4%+76.9%
Per year+0.0%-68.1%
Volatility (annualized)0.0%440.4%
Max drawdown+0.0% (→)-100.0% (Oct 2021→May 2024)

BSPM analyst estimates and revisions

PeriodEPS estimate90 days agoChangeRevenue estimateAnalysts
Current quarter———$0—
Next quarter———$0—
Current fiscal year (ends Dec 2013)———$0—
Next fiscal year———$0—

Key Statistics (as of October 24, 2026 at 02:20 UTC)

PriceUSD 0
Change▲ 0.00% (up)
Previous CloseUSD 0
OpenUSD 0
Day RangeUSD 0 – 0
52-Week RangeUSD 0 – 0
Volume150 shares
Market Cap$263
ExchangePNK

Technical Analysis (BSPM)

Nexqual's technical model rates BSPM "STRONG SELL" based on 0 bullish and 5 bearish signals across 126 daily candles, as of October 24, 2026 at 02:20 UTC.

Overall SignalSTRONG SELL
RSI (14)100 (overbought)
vs SMA50Below (USD 0)
MACD0 (negative)

Analyst Ratings (BSPM)

Wall Street analysts rate BSPM "None", per Nexqual as of October 24, 2026 at 02:20 UTC.

Consensus RatingNone

Earnings (BSPM)

Source: Nexqual, October 24, 2026 at 02:20 UTC.

Financials & Fundamentals (BSPM)

Total Revenue$317,794
Gross Margin-11.56%
Operating Margin+876.46%
Profit Margin+294.01%
ROE+2.66%
Debt / Equity0.07
Current Ratio0.19
Total Cash$364,973
Total Debt$2.43M

Source: Nexqual, October 24, 2026 at 02:20 UTC.

Financial Health Score (BSPM)

Nexqual rates Biostar Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of October 24, 2026 at 02:20 UTC.

GrowthMixed — No data
ProfitabilityCritical — Gross margin -12% (last 12 months)
Balance SheetSolid — $365K cash vs $2M debt
Cash FlowSolid — Operating cash flow $9M (TTM)
EfficiencyWeak — ROE 3%, ROA 4.2%

Ownership (BSPM)

Insider Ownership+0.00%
Institutional Ownership+0.00%
Shares Outstanding2.64M
Float2.21M
Short % of Float+7.22%

Source: Nexqual, October 24, 2026 at 02:20 UTC.

Leadership (BSPM)

Biostar Pharmaceuticals, Inc. is led by Ronghua Wang, Chairman, CEO & President, per Nexqual as of October 24, 2026 at 02:20 UTC.

Chairman, CEO & PresidentRonghua Wang
Chief Operating OfficerZhenghong Wang
Chief Financial OfficerXiaojuan Zhai
Director of Administration & Secretary of BoardShuang Gong

Peers & Related Stocks

SymbolNamePriceChange
SUPNSupernus Pharmaceuticals, Inc.USD 40.7▼ 3.26%
BHCBausch Health Companies Inc.USD 6.44▼ 0.77%
HCMHUTCHMED (China) LimitedUSD 14.36▲ 0.56%
AMLXAmylyx Pharmaceuticals, Inc.USD 27.2▼ 4.8%
RGCRegencell Bioscience Holdings LUSD 7.67▼ 21.81%
LQDALiquidia CorporationUSD 42.65▲ 7.46%

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 02:20 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt